Interleukin-36 promotes systemic Type-I IFN responses in severe psoriasis.
M. Catapano, M. Vergnano, M. Romano, S. K. Mahil, S.-E. Choon, D. A. Burden, H. S. Young, I. M. Carr, H. J. Lachmann, G. Lombardi, C. Smith, F. D. Ciccarelli, J. N. Barker, F. Capon
The paper identifies an IL-36/TLR-9/Type-I IFN axis that drives systemic inflammation in psoriasis, offering a potential therapeutic target.
bioRxiv · Dec 14, 2018 · PreprintImmunology